经颅多普勒作为筛查试验排除脑损伤患者颅内高压:IMPRESSIT-2 前瞻性多中心国际研究
本研究为前瞻性、国际、多中心、非盲诊断准确性研究,纳入需有创颅内压监测(ICPi)的急性脑损伤患者(TBI、SAH、ICH 或 IS)262 例,在 16 个国际 ICU 中于置管前、置管后即刻及置管后 2–3 小时比较 ICPtcd 与 ICPi。颅内高压(>22 mmHg)发生 87 例(33.2%),共 687 对配对比较;ICPtcd 的阴性预测值在 ICP >20、>22、>25 mmHg 阈值下分别为 91.3%、95.6%、98.6%。ICPtcd 与 ICPi 一致性相关系数 33.3%(95% CI 25.6–40.5%),Bland-Altman 平均偏倚 -3.3 mmHg;排除颅内高压的最佳 ICPtcd 阈值为 20.5 mmHg,敏感度 70%(95% CI 40.7–92.6%),特异度 72%(95% CI 51.9–94.0%),AUC 76%(95% CI 65.6–85.5%)。作者认为 ICPtcd 在无法使用有创方法时可能有助于排除颅内高压。
要点
- ICPtcd 排除颅内高压的阴性预测值高:ICP >20 mmHg 时 91.3%,>22 mmHg 时 95.6%,>25 mmHg 时 98.6%。
- 最佳排除阈值为 ICPtcd 20.5 mmHg,敏感度 70%(95% CI 40.7–92.6%),特异度 72%(95% CI 51.9–94.0%),AUC 76%(95% CI 65.6–85.5%)。
- ICPtcd 与 ICPi 的一致性相关系数仅 33.3%(95% CI 25.6–40.5%),Bland-Altman 平均偏倚 -3.3 mmHg。
- 研究纳入需有创颅内压监测的 TBI、SAH、ICH 或 IS 患者 262 例,颅内高压(>22 mmHg)发生 87 例(33.2%),共 687 对配对比较。
- 作者认为 ICPtcd 在无法使用有创方法或不可用时可能有助于临床排除颅内高压。
适用人群与场景
- 急性脑损伤患者,属于创伤性脑损伤(TBI)、蛛网膜下腔出血(SAH)、脑出血(ICH)或缺血性卒中(IS)四类之一,且需要有创颅内压监测(ICPi)。
- 研究在 16 个国际重症监护病房(ICU)进行。
诊断标准与关键阈值
- 颅内高压定义参考标准为有创颅内压监测(ICPi)>22 mmHg;研究同时在 >20 mmHg、>22 mmHg 和 >25 mmHg 三个阈值下评估 ICPtcd。
- 排除颅内高压的最佳 ICPtcd 阈值为 20.5 mmHg。
研究设计与关键结果
- 研究类型:前瞻性、国际、多中心、非盲诊断准确性研究,比较指数试验 ICPtcd 与参考标准 ICPi。
- 样本量:262 例患者纳入最终分析,共 687 对 ICPtcd 与 ICPi 配对比较;颅内高压(>22 mmHg)发生 87 例(33.2%)。
- ICPtcd 阴性预测值:ICP >20 mmHg 时为 91.3%,>22 mmHg 时为 95.6%,>25 mmHg 时为 98.6%。
- ICPtcd 与 ICPi 的一致性相关系数为 33.3%(95% CI 25.6–40.5%),Bland-Altman 分析显示平均偏倚 -3.3 mmHg。
- 最佳 ICPtcd 阈值 20.5 mmHg 排除颅内高压:敏感度 70%(95% CI 40.7–92.6%),特异度 72%(95% CI 51.9–94.0%),AUC 76%(95% CI 65.6–85.5%)。
证据类型、等级与局限
- 证据类型:前瞻性、国际、多中心、非盲诊断准确性研究。
- 试验注册号:NCT02322970。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为 ICPtcd 具有高阴性预测值,在无法使用有创方法或不可用时可能有助于临床排除颅内高压。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Alternative noninvasive methods capable of excluding intracranial hypertension through use of transcranial Doppler (ICPtcd) in situations where invasive methods cannot be used or are not available would be useful during the management of acutely brain-injured patients. The objective of this study was to determine whether ICPtcd can be considered a reliable screening test compared to the reference standard method, invasive ICP monitoring (ICPi), in excluding the presence of intracranial hypertension.
METHODS: This was a prospective, international, multicenter, unblinded, diagnostic accuracy study comparing the index test (ICPtcd) with a reference standard (ICPi), defined as the best available method for establishing the presence or absence of the condition of interest (i.e., intracranial hypertension). Acute brain-injured patients pertaining to one of four categories: traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) requiring ICPi monitoring, were enrolled in 16 international intensive care units. ICPi measurements (reference test) were compared to simultaneous ICPtcd measurements (index test) at three different timepoints: before, immediately after and 2 to 3 h following ICPi catheter insertion. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) were calculated at three different ICPi thresholds (> 20, > 22 and > 25 mmHg) to assess ICPtcd as a bedside real-practice screening method. A receiver operating characteristic (ROC) curve analysis with the area under the curve (AUC) was used to evaluate the discriminative accuracy and predictive capability of ICPtcd.
RESULTS: Two hundred and sixty-two patients were recruited for final analysis. Intracranial hypertension (> 22 mmHg) occurred in 87 patients (33.2%). The total number of paired comparisons between ICPtcd and ICPi was 687. The NPV was elevated (ICP > 20 mmHg = 91.3%, > 22 mmHg = 95.6%, > 25 mmHg = 98.6%), indicating high discriminant accuracy of ICPtcd in excluding intracranial hypertension. Concordance correlation between ICPtcd and ICPi was 33.3% (95% CI 25.6-40.5%), and Bland-Altman showed a mean bias of -3.3 mmHg. The optimal ICPtcd threshold for ruling out intracranial hypertension was 20.5 mmHg, corresponding to a sensitivity of 70% (95% CI 40.7-92.6%) and a specificity of 72% (95% CI 51.9-94.0%) with an AUC of 76% (95% CI 65.6-85.5%).
CONCLUSIONS AND RELEVANCE: ICPtcd has a high NPV in ruling out intracranial hypertension and may be useful to clinicians in situations where invasive methods cannot be used or not available.
TRIAL REGISTRATION: NCT02322970 .
参考来源
- Rasulo FA, Calza S, Robba C, et al. Transcranial Doppler as a screening test to exclude intracranial hypertension in brain-injured patients: the IMPRESSIT-2 prospective multicenter international study. Crit Care. 2022. PMID: 35428353. doi:10.1186/s13054-022-03978-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。